Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8TE12

UPID:
LMX1A_HUMAN

ALTERNATIVE NAMES:
LIM/homeobox protein 1.1; LIM/homeobox protein LMX1A

ALTERNATIVE UPACC:
Q8TE12; B3KXP6; Q0VDB5; Q5VWG4; Q8TE11

BACKGROUND:
The protein LIM homeobox transcription factor 1-alpha, with alternative names LIM/homeobox protein 1.1 and LMX1A, is essential for specifying dorsal cell fates in the CNS and developing vertebrae. It acts by binding to an A/T-rich sequence in the insulin gene promoter, serving as a transcriptional activator required for roof plate development.

THERAPEUTIC SIGNIFICANCE:
Linked to the progressive condition Deafness, autosomal dominant, 7 (DFNA7), LMX1A's involvement in sensorineural hearing loss highlights its potential as a therapeutic target. The exploration of LIM homeobox transcription factor 1-alpha's function offers promising avenues for developing treatments for hearing impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.